VR Adviser
Latest statistics and disclosures from Venrock Adviser's latest quarterly 13F-HR filing:
- Top 5 stock holdings are APGE, ORKA, ERAS, SYRE, DNTH, and represent 67.61% of Venrock Adviser's stock portfolio.
- Added to shares of these 9 stocks: ERAS (+$28M), ACHV (+$18M), Parabilis Medicines (+$17M), RLMD (+$14M), XFOR (+$7.5M), SVRA (+$6.2M), ARTV, Research Alliance Corp Iii, INM.
- Started 4 new stock positions in INM, ACHV, Parabilis Medicines, Research Alliance Corp Iii.
- Reduced shares in these 9 stocks: Kalvista Pharmaceuticals (-$130M), SYRE (-$62M), ELVN (-$61M), Engene Holdings (-$33M), TENX (-$27M), CTMX (-$19M), COGT (-$14M), SEPN (-$12M), VRDN (-$12M).
- Sold out of its positions in Engene Holdings, Kalvista Pharmaceuticals, SEPN, TENX.
- Venrock Adviser was a net seller of stock by $-271M.
- Venrock Adviser has $3.3B in assets under management (AUM), dropping by 23.10%.
- Central Index Key (CIK): 0001615982
Tip: Access up to 7 years of quarterly data
Positions held by VR Adviser consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Venrock Adviser
Venrock Adviser holds 33 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Apogee Therapeutics (APGE) | 34.2 | $1.1B | 8.5M | 132.73 |
|
|
| Oruka Therapeutics (ORKA) | 12.0 | $395M | 4.1M | 95.17 |
|
|
| Erasca (ERAS) | 9.9 | $328M | +9% | 18M | 18.32 |
|
| Spyre Therapeutics Com New (SYRE) | 8.0 | $265M | -18% | 3.0M | 88.78 |
|
| Dianthus Therapeutics (DNTH) | 3.5 | $115M | 1.2M | 97.48 |
|
|
| Ocular Therapeutix (OCUL) | 3.1 | $102M | 10M | 9.82 |
|
|
| Damora Therapeutics Com New (DMRA) | 2.8 | $94M | 3.6M | 26.01 |
|
|
| Savara (SVRA) | 2.8 | $91M | +7% | 15M | 6.16 |
|
| Jade Biosciences Com New (JBIO) | 2.2 | $72M | 3.2M | 22.22 |
|
|
| Cogent Biosciences (COGT) | 1.9 | $64M | -17% | 1.6M | 38.70 |
|
| Miragen Therapeutics (VRDN) | 1.8 | $60M | -16% | 3.3M | 18.37 |
|
| Vor Biopharma Com New (VOR) | 1.7 | $56M | 3.0M | 18.41 |
|
|
| Dyne Therapeutics (DYN) | 1.5 | $48M | 2.2M | 22.21 |
|
|
| Maze Therapeatics (MAZE) | 1.4 | $48M | 1.6M | 29.84 |
|
|
| Relmada Therapeutics (RLMD) | 1.4 | $47M | +41% | 6.8M | 6.92 |
|
| Oric Pharmaceuticals (ORIC) | 1.4 | $47M | 4.3M | 10.83 |
|
|
| Crescent Biopharma (CBIO) | 1.2 | $38M | 2.1M | 18.00 |
|
|
| Zura Bio Class A Ord Shs (ZURA) | 1.2 | $38M | 6.4M | 5.90 |
|
|
| Adlai Nortye Sponsored Ads (ANL) | 1.1 | $37M | 3.2M | 11.50 |
|
|
| Enliven Therapeutics (ELVN) | 0.8 | $27M | -69% | 526k | 50.75 |
|
| Cybin Com New (HELP) | 0.8 | $26M | 3.9M | 6.61 |
|
|
| Cullinan Oncology (CGEM) | 0.8 | $25M | 1.4M | 18.21 |
|
|
| Century Therapeutics (IPSC) | 0.6 | $21M | 8.7M | 2.45 |
|
|
| Artiva Biotherapeutics (ARTV) | 0.6 | $20M | +26% | 2.0M | 9.70 |
|
| Cytomx Therapeutics (CTMX) | 0.6 | $19M | -50% | 5.0M | 3.75 |
|
| Achieve Life Sciences (ACHV) | 0.5 | $18M | NEW | 2.8M | 6.53 |
|
| Parabilis Medicines | 0.5 | $17M | NEW | 625k | 27.37 |
|
| Surrozen Com New (SRZN) | 0.5 | $16M | 633k | 25.95 |
|
|
| Korro Bio (KRRO) | 0.4 | $13M | 1.0M | 13.18 |
|
|
| Alto Neuroscience Com Shs (ANRO) | 0.4 | $13M | 500k | 26.39 |
|
|
| X4 Pharmaceuticals Com New (XFOR) | 0.3 | $9.0M | +485% | 1.9M | 4.67 |
|
| Research Alliance Corp Iii Ord Shs Cl A | 0.1 | $3.2M | NEW | 300k | 10.70 |
|
| Inmed Pharmaceuticals Com New (INM) | 0.0 | $51k | NEW | 33k | 1.55 |
|
Past Filings by Venrock Adviser
SEC 13F filings are viewable for Venrock Adviser going back to 2020
- Venrock Adviser 2026 Q2 filed Aug. 14, 2026
- Venrock Adviser 2026 Q1 filed May 15, 2026
- VR Adviser 2025 Q4 filed Feb. 17, 2026
- VR Adviser 2025 Q3 filed Nov. 14, 2025
- VR Adviser 2025 Q2 filed Aug. 14, 2025
- VR Adviser 2025 Q1 filed May 15, 2025
- VR Adviser 2024 Q4 filed Feb. 14, 2025
- VR Adviser 2024 Q3 filed Nov. 14, 2024
- VR Adviser 2024 Q2 filed Aug. 14, 2024
- VR Adviser 2024 Q1 filed May 15, 2024
- VR Adviser 2023 Q4 filed Feb. 14, 2024
- VR Adviser 2023 Q3 filed Nov. 14, 2023
- VR Adviser 2023 Q2 filed Aug. 11, 2023
- VR Adviser 2022 Q2 restated filed May 15, 2023
- VR Adviser 2022 Q3 restated filed May 15, 2023
- VR Adviser 2022 Q4 restated filed May 15, 2023